75 results
Page 2 of 4
8-K
EX-99.1
jo3z30q4s svd
13 Feb 24
Results of Operations and Financial Condition
4:10pm
8-K
EX-99.1
0nolqd 0lkg
6 Feb 24
Immunome To Acquire AL102, A Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
8:05am
8-K
EX-99.1
pvfhw8
11 Jan 24
Regulation FD Disclosure
5:27pm
8-K/A
EX-99.3
k5nqcrh5wzxctfan2v9v
22 Nov 23
Report of Independent Auditors
4:02pm
8-K
EX-99.1
l1c10b9j93a372x a2g
15 Nov 23
Regulation FD Disclosure
6:03am
8-K
EX-99.1
cs773oze5bl4mhyzh
9 Nov 23
Immunome Reports Third Quarter 2023 Financial Results
4:52pm
424B3
stnyu8qhm3 29wv
28 Aug 23
Prospectus supplement
9:10am
S-4/A
2h0cu2s9 1m
25 Aug 23
Registration of securities issued in business combination transactions (amended)
6:38am
8-K
EX-99.1
0cx nk79x1
9 Aug 23
Immunome Reports Second Quarter 2023 Financial Results
8:27am
S-4
89ch4mcahgdhapmz8
8 Aug 23
Registration of securities issued in business combination transactions
4:07pm
425
EX-99.1
805lzay sj1
5 Jul 23
Business combination disclosure
5:15pm
8-K
EX-99.1
wyau5o467dcbsc
5 Jul 23
Morphimmune and Immunome Combined Corporate Presentation July 2023
5:12pm
425
EX-99.2
qwhs3wi4gbu9j
29 Jun 23
Business combination disclosure
9:10am
425
EX-10.4
0v0bbzyc
29 Jun 23
Business combination disclosure
9:10am
8-K
EX-10.4
bu2qo8ang90qq2
29 Jun 23
Immunome and Morphimmune Announce Definitive Merger Agreement
9:08am
8-K
EX-99.2
uo9b7ee8dd
29 Jun 23
Immunome and Morphimmune Announce Definitive Merger Agreement
9:08am
8-K
EX-99.1
79h8g4g3jztbg
5 May 23
Immunome Reports First Quarter 2023 Financial Results
8:19am